Article

Association between mild anemia and executive function impairment in community-dwelling older women: The Women's Health and Aging Study II

Center on Aging and Health and Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, USA.
Journal of the American Geriatrics Society (Impact Factor: 4.22). 10/2006; 54(9):1429-35. DOI: 10.1111/j.1532-5415.2006.00863.x
Source: PubMed

ABSTRACT To evaluate the relationship between mild anemia and executive function in community-dwelling older women.
Cross-sectional.
Community-based.
High-functioning subjects participating in the baseline assessment of the Women's Health and Aging Study (WHAS) II, Baltimore, Maryland, 1994 to 1996. WHAS II eligibility criteria included aged 70 to 80, a Mini-Mental State Examination score of 24 or greater, and absence of advanced disability (difficulty in no more than 1 domain of physical function). Included in this study were 364 subjects with a hemoglobin concentration 10 g/dL or greater and known executive function status.
Trail Making Test (TMT) Parts B and A. Tertiles of time to complete each test were used to define best (bottom), intermediate, and worst (top) performance. Tertiles of the difference TMT-B minus TMT-A were calculated. Anemia defined as hemoglobin concentration less than 12 g/dL.
The percentage of subjects in the worst TMT-B, TMT-A, and TMT-B minus TMT-A performance tertile was highest for those with anemia. Prevalent anemia substantially increased the likelihood of performing worst (as opposed to best) on the TMT-B (odds ratio (OR) = 5.2, 95% confidence interval (CI) = 1.3-20.5), TMT-A (OR = 4.8, 95% CI = 1.5-15.6), and TMT-B minus TMT-A (OR = 4.2, 95% CI = 1.0-17.2), even after controlling for age, education, race, prevalent diseases, and relevant physiological and functional parameters.
This study provides preliminary evidence in support of the hypothesis that mild anemia might be an independent risk factor for executive function impairment in community-dwelling older adults. Whether such an association is causal or noncausal remains to be determined.

Download full-text

Full-text

Available from: Michelle C Carlson, Jul 04, 2015
1 Follower
 · 
61 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Anemia of inflammation or chronic disease is a highly prevalent form of anemia. The inflammatory cytokine interleukin-6 (IL-6) negatively correlates with hemoglobin concentration in many disease states. The IL-6-hepcidin antimicrobial peptide axis promotes iron-restricted anemia; however the full role of IL-6 in anemia of inflammation is not well-defined. We previously reported that chronic inflammation had a negative impact on maturation of erythroid progenitors in a mouse model. We hypothesized that IL-6 may be responsible for impaired erythropoiesis, independent of iron restriction. To test the hypothesis we utilized the human erythroleukemia TF-1 cell line to model erythroid maturation and exposed them to varying doses of IL-6 over six days. At 10ng/ml, IL-6 significantly repressed erythropoietin-dependent TF-1 erythroid maturation. While IL-6 did not decrease the expression of genes associated with hemoglobin synthesis, we observed impaired hemoglobin synthesis as demonstrated by decreased benzidine staining. We also observed that IL-6 down regulated expression of the gene SLC4a1 which is expressed late in erythropoiesis. Those findings suggested that IL-6-dependent inhibition of hemoglobin synthesis might occur. We investigated the impact of IL-6 on mitochondria. IL-6 decreased the mitochondrial membrane potential at all treatment doses, and significantly decreased mitochondrial mass at the highest dose. Our studies indicate that IL-6 may impair mitochondrial function in maturing erythroid cells resulting in impaired hemoglobin production and erythroid maturation. Our findings may indicate a novel pathway of action for IL-6 in the anemia of inflammation, and draw attention to the potential for new therapeutic targets that affect late erythroid development.
    Blood Cells Molecules and Diseases 10/2013; DOI:10.1016/j.bcmd.2013.09.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anemia is a common disorder in the elderly and is associated with increased morbidity and mortality. In elderly subjects, in whom anemia is highly prevalent, there are several aspects, such as a hemoglobin at a level which should concern us limit, or identifying its causes, that are not easy to establish. This review focuses on knowing what is considered to be normal hemoglobin levels in adults and the common causes and potential consequences of anemia in elderly patients. It provides a diagnostic algorithm and an approach to treatment that addresses new treatments such as parenteral iron drugs and erythropoiesis-stimulating agents.
    Revista Española de Geriatría y Gerontología 45(5):291-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anämie ist keine physiologische Erscheinung des höheren Lebensalters, sondern Symptom einer zugrunde liegenden Erkrankung. Die Frage nach Abklärung dieser Erkrankung muss individuell entschieden werden, abhängig von Patientenwunsch, geriatrischem Assessment und Therapieoptionen. Dabei sind Lebensqualität und Lebenserwartung zu berücksichtigen. Die Prävalenz der Anämie im Alter ist hoch und betrifft unter stationär behandelten geriatrischen Patienten fast jeden zweiten. Die Ursachen sind vielfältig, wobei die häufigsten Formen im höheren Lebensalter die Eisenmangelanämie (IDA), die Anämie chronischer Erkrankungen (ACD) und die unklare Anämie (UA) sind. Daher beschränkt sich dieser Beitrag auf Diagnostik und Therapie dieser Formen. Es gibt bis heute keine Leitlinie für die Diagnostik und Therapie der Anämie im Alter. Als diagnostische Basis bietet sich die Erfassung von Blutbild, Ferritin und Transferrinsättigung an. Die therapeutischen Maßnahmen richten sich nach der Grunderkrankung.
    Zeitschrift für Gerontologie + Geriatrie 02/2013; 46(2). DOI:10.1007/s00391-012-0453-9